Barinthus Biotherapeutics plc American (BRNS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BRNS SEC filings page.
Barinthus Biotherapeutics plc American (BRNS) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Barinthus's development-stage model relies on R&D-led spending, intermittent revenue, and recurring cash needs rather than debt-heavy financing.
In FY2024, operating cash flow of-$28.9M was less negative than net income of-$61.1M , showing the accounting loss did not translate one-for-one into cash use. Yet free cash flow remained-$29.8M , so the improvement reflected the income-to-cash reconciliation rather than internally generated cash.
FY2024 R&D reached
A FY2024 current ratio of 8.0x alongside debt-to-equity of 0.2x describes substantial short-term coverage with modest leverage, not debt-funded operations. Reported liquidity equaled 17.6 months of the latest annual operating outflow, but total assets declined between FY2023 and FY2024 while operating cash flow stayed negative, indicating resources were being consumed rather than replenished internally.
Financial Health Signals
Barinthus Biotherapeutics plc American does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Barinthus Biotherapeutics plc American scores -5.12, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($30.2M) relative to total liabilities ($23.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Barinthus Biotherapeutics plc American passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Barinthus Biotherapeutics plc American reported a net loss of $66.4M while operations used $48.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Barinthus Biotherapeutics plc American reported an operating loss of $70.6M against $51K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Barinthus Biotherapeutics plc American's EBITDA was -$10.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the same quarter a year earlier. Against the prior quarter it is down 95.8%.
Barinthus Biotherapeutics plc American reported -$10.6M in net income in Q2 2026. This represents an increase of 49.9% from the same quarter a year earlier. Against the prior quarter it is down 91.3%.
Barinthus Biotherapeutics plc American earned -$0.26 per diluted share (EPS) in Q2 2026. This represents an increase of 50.0% from the same quarter a year earlier. Against the prior quarter it is down 85.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Barinthus Biotherapeutics plc American recorded an outflow of $8.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 55.4% from the same quarter a year earlier. Against the prior quarter it is down 140.4%.
Barinthus Biotherapeutics plc American held $59.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Barinthus Biotherapeutics plc American's ROE was -18.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Barinthus Biotherapeutics plc American invested $3.9M in research and development in Q2 2026. This represents a decrease of 50.7% from the same quarter a year earlier. Against the prior quarter it is up 9.2%.
Barinthus Biotherapeutics plc American reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
BRNS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0-100.0% | N/A | N/A | N/A | $15.0M |
| R&D Expenses | $3.9M-50.7% | $3.6M-56.7% | N/A | $5.4M-51.6% | $8.0M-31.8% | $8.3M-25.5% | N/A | $11.1M-26.4% |
| SG&A Expenses | $7.1M-53.8% | $2.5M-80.0% | N/A | $5.2M-61.5% | $15.4M+113.6% | $12.6M+110.9% | N/A | $13.4M+1296.5% |
| Operating Income | -$11.0M+52.8% | -$6.1M+70.5% | N/A | -$15.1M-60.6% | -$23.3M-27.6% | -$20.6M-21.8% | N/A | -$9.4M+41.8% |
| EBITDA | -$10.2M+52.1% | -$5.2M+71.9% | N/A | -$14.2M-79.8% | -$21.3M-27.0% | -$18.6M-19.9% | N/A | -$7.9M+46.0% |
| Interest Expense | $14K+16.7% | $13K0.0% | N/A | $13K-23.5% | $12K0.0% | $13K+8.3% | N/A | $17K+142.9% |
| Income Tax | -$23K+8.0% | -$16K+27.3% | N/A | -$71K-2266.7% | -$25K-257.1% | -$22K+40.5% | N/A | -$3K+99.5% |
| Net Income | -$10.6M+49.9% | -$5.5M+71.8% | N/A | -$14.6M-79.5% | -$21.1M-24.8% | -$19.6M-26.9% | N/A | -$8.1M+42.3% |
| EPS (Basic) | -$0.26+50.0% | -$0.14+71.4% | -$0.27+47.1% | -$0.36-71.4% | -$0.52-20.9% | -$0.49-22.5% | -$0.51-13.3% | -$0.21+43.2% |
| EPS (Diluted) | -$0.26+50.0% | -$0.14+71.4% | -$0.27+47.1% | -$0.36-71.4% | -$0.52-20.9% | -$0.49-22.5% | -$0.51-13.3% | -$0.21+43.2% |
| Diluted Shares (Avg) | 41M+1.3% | 41M+1.4% | N/A | 41M+3.1% | 40M+3.3% | 40M+3.8% | N/A | 39M+2.3% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BRNS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $81.9M-36.8% | $92.1M-35.1% | $98.2M-38.8% | $109.2M-42.1% | $129.6M-30.6% | $142.0M-28.8% | $160.3M-25.3% | $188.7M-18.0% |
| Current Assets | $63.3M-37.0% | $72.7M-33.9% | $77.8M-38.1% | $86.8M-35.6% | $100.4M-23.9% | $109.9M-23.2% | $125.7M-19.9% | $134.7M-21.3% |
| Cash & Equivalents | $59.3M-31.3% | $65.9M-33.6% | $70.5M-36.3% | $74.3M-30.0% | $86.3M-26.8% | $99.1M-23.7% | $110.7M-22.1% | $106.1M-33.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $12.2M0.0% |
| Total Liabilities | $24.8M-8.6% | $25.7M-2.8% | $23.9M-20.9% | $24.6M-15.7% | $27.1M-9.6% | $26.4M-3.9% | $30.2M+9.7% | $29.2M-15.0% |
| Current Liabilities | $11.4M-10.2% | $12.0M+0.2% | $10.0M-36.0% | $10.8M-28.4% | $12.7M-18.4% | $12.0M-6.7% | $15.7M+24.3% | $15.1M-18.8% |
| Non-Current Liabilities | $13.3M-7.1% | $13.7M-5.3% | $13.9M-4.7% | $13.8M-2.2% | $14.4M-0.1% | $14.4M-1.4% | $14.5M-2.5% | $14.2M-10.4% |
| Total Equity | $57.1M-44.3% | $66.4M-42.5% | $74.2M-42.9% | $84.5M-47.0% | $102.4M-34.6% | $115.5M-32.8% | $130.0M-30.4% | $159.3M-18.5% |
| Retained Earnings | -$320.2M-15.0% | -$309.6M-20.3% | -$304.1M-28.0% | -$293.0M-34.9% | -$278.4M-33.2% | -$257.3M-34.0% | -$237.7M-34.6% | -$217.1M-36.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
BRNS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.1M+55.3% | -$3.4M+77.4% | -$4.2M-132.4% | -$10.7M+41.1% | -$18.1M-50.8% | -$14.9M-26.1% | $13.1M+166.8% | -$18.2M-62.6% |
| Depreciation & Amortization | $800K-60.0% | $856K-57.9% | $909K-36.3% | $900K-40.0% | $2.0M+33.3% | $2.0M+42.2% | $1.4M-0.5% | $1.5M0.0% |
| Stock-Based Compensation | $433K+254.1% | $556K+18.8% | N/A | -$415K-136.3% | -$281K-123.5% | $468K-71.0% | N/A | $1.1M+1907.0% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $32K-83.3% | $5K-98.4% | $278K+81.7% | $114K+216.7% |
| Free Cash Flow | -$8.1M+55.4% | -$3.4M+77.4% | -$4.2M-133.1% | -$10.7M+41.4% | -$18.1M-48.7% | -$14.9M-22.9% | $12.8M+164.8% | -$18.3M-63.1% |
| Investing Cash Flow | $61K+290.6% | $55K+1200.0% | $2K+100.7% | $451K+495.6% | -$32K+83.3% | -$5K+98.4% | -$278K-281.7% | -$114K-216.7% |
| Financing Cash Flow | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $2K-99.6% | $837K+667.9% | $465K+910.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BRNS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -62.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -54.2% |
| Return on Equity | -18.5%+2.1pp | -8.3%+8.7pp | N/A | -17.3%-12.2pp | -20.6%-9.8pp | -17.0%-8.0pp | N/A | -5.1%+2.1pp |
| Return on Assets | -12.9%+3.4pp | -6.0%+7.8pp | N/A | -13.3%-9.0pp | -16.3%-7.2pp | -13.8%-6.1pp | N/A | -4.3%+1.8pp |
| Current Ratio | 5.54-2.4x | 6.05-3.1x | 7.76-0.3x | 8.04-0.9x | 7.89-0.6x | 9.18-2.0x | 8.03-4.4x | 8.93-0.3x |
| Debt-to-Equity | 0.43+0.2x | 0.39+0.2x | 0.32+0.1x | 0.29+0.1x | 0.26+0.1x | 0.23+0.1x | 0.23+0.1x | 0.180.0x |
| Asset Turnover | N/A | N/A | N/A | 0.00-0.1x | N/A | N/A | N/A | 0.08+0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -122.3% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Barinthus Biotherapeutics plc American BRNS | FY2025 | $0 | -$66.4M | N/A | $30.2M | — |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $13.3M | — |
| PLUS THERAPEUTICS, Inc. PSTV | FY2025 | $5.2M | -$22.4M | N/A | $26.6M | 31/100 |
| Radiopharm Theranostics Limited American RADX | FY2025 | $3.6M | -$38.3M | N/A | $29.8M | 20/100 |
| Annovis Bio, Inc. ANVS | FY2025 | $0 | -$28.9M | N/A | $50.7M | — |
| Century Therapeutics, Inc. IPSC | FY2025 | $109.2M | -$9.6M | -8.8% | $351.3M | 59/100 |
Where Barinthus Biotherapeutics plc American Ranks
Frequently Asked Questions
What is Barinthus Biotherapeutics plc American's annual revenue?
Barinthus Biotherapeutics plc American (BRNS) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Barinthus Biotherapeutics plc American's revenue growing?
Barinthus Biotherapeutics plc American (BRNS) revenue declined by 100.0% year-over-year, from $15.0M to $0 in fiscal year 2025.
Is Barinthus Biotherapeutics plc American profitable?
No, Barinthus Biotherapeutics plc American (BRNS) reported a net income of -$66.4M in fiscal year 2025.
What is Barinthus Biotherapeutics plc American's EBITDA?
Barinthus Biotherapeutics plc American (BRNS) had EBITDA of -$64.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Barinthus Biotherapeutics plc American's return on equity (ROE)?
Barinthus Biotherapeutics plc American (BRNS) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Barinthus Biotherapeutics plc American's free cash flow?
Barinthus Biotherapeutics plc American (BRNS) recorded an outflow of $48.0M in free cash flow during fiscal year 2025. This represents a -61.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Barinthus Biotherapeutics plc American's operating cash flow?
Barinthus Biotherapeutics plc American (BRNS) recorded an outflow of $48.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Barinthus Biotherapeutics plc American's total assets?
Barinthus Biotherapeutics plc American (BRNS) had $98.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Barinthus Biotherapeutics plc American's capital expenditures?
Barinthus Biotherapeutics plc American (BRNS) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Barinthus Biotherapeutics plc American spend on research and development?
Barinthus Biotherapeutics plc American (BRNS) invested $25.6M in research and development during fiscal year 2025.
What is Barinthus Biotherapeutics plc American's current ratio?
Barinthus Biotherapeutics plc American (BRNS) had a current ratio of 7.76 as of fiscal year 2025, which is generally considered healthy.
What is Barinthus Biotherapeutics plc American's debt-to-equity ratio?
Barinthus Biotherapeutics plc American (BRNS) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Barinthus Biotherapeutics plc American's return on assets (ROA)?
Barinthus Biotherapeutics plc American (BRNS) had a return on assets of -67.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Barinthus Biotherapeutics plc American's P/E ratio?
Barinthus Biotherapeutics plc American (BRNS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $30.2M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Barinthus Biotherapeutics plc American's price-to-sales ratio?
Barinthus Biotherapeutics plc American (BRNS) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $30.2M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Barinthus Biotherapeutics plc American's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Barinthus Biotherapeutics plc American (BRNS) held $70.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $48.0M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Barinthus Biotherapeutics plc American's Altman Z-Score?
Barinthus Biotherapeutics plc American (BRNS) has an Altman Z-Score of -5.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Barinthus Biotherapeutics plc American's Piotroski F-Score?
Barinthus Biotherapeutics plc American (BRNS) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Barinthus Biotherapeutics plc American's earnings high quality?
Barinthus Biotherapeutics plc American (BRNS) reported a net loss of $66.4M while operations used $48.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Barinthus Biotherapeutics plc American cover its interest payments?
Barinthus Biotherapeutics plc American (BRNS) reported an operating loss of $70.6M against $51K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.